NEW YORK, June 15 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it will be added to the broad-market Russell 3000(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2009. According to the preliminary list of additions posted June 12, 2009 on www.russell.com, selection to the Russell 3000(R) Index means Delcath is automatically included in the popular Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.
Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.
About Delcath Systems, Inc.:
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
|SOURCE Delcath Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved